No Signs of Neuroinflammation in Women With Chronic Fatigue Syndrome or Q Fever Fatigue Syndrome Using the TSPO Ligand [
Adolescent
Adult
Amides
/ pharmacokinetics
Brain
/ diagnostic imaging
Fatigue
/ diagnostic imaging
Fatigue Syndrome, Chronic
/ diagnostic imaging
Female
Humans
Isoquinolines
/ pharmacokinetics
Middle Aged
Neuroinflammatory Diseases
/ diagnostic imaging
Positron-Emission Tomography
Q Fever
/ complications
Receptors, GABA
Young Adult
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
20
05
2021
accepted:
15
09
2021
entrez:
24
11
2021
pubmed:
25
11
2021
medline:
12
3
2022
Statut:
epublish
Résumé
The pathophysiology of chronic fatigue syndrome (CFS) and Q fever fatigue syndrome (QFS) remains elusive. Recent data suggest a role for neuroinflammation as defined by increased expression of translocator protein (TSPO). In the present study, we investigated whether there are signs of neuroinflammation in female patients with CFS and QFS compared with healthy women, using PET with the TSPO ligand The study population consisted of patients with CFS (n = 9), patients with QFS (n = 10), and healthy subjects (HSs) (n = 9). All subjects were women, matched for age (±5 years) and neighborhood, aged between 18 and 59 years, who did not use any medication other than paracetamol or oral contraceptives, and were not vaccinated in the last 6 months. None of the subjects reported substance abuse in the past 3 months or reported signs of underlying psychiatric disease on the Mini-International Neuropsychiatric Interview. All subjects underwent a [ No statistically significant differences in BP In contrast to what was previously reported for CFS, we found no significant difference in BP EudraCT number 2014-004448-37.
Sections du résumé
BACKGROUND AND OBJECTIVES
The pathophysiology of chronic fatigue syndrome (CFS) and Q fever fatigue syndrome (QFS) remains elusive. Recent data suggest a role for neuroinflammation as defined by increased expression of translocator protein (TSPO). In the present study, we investigated whether there are signs of neuroinflammation in female patients with CFS and QFS compared with healthy women, using PET with the TSPO ligand
METHODS
The study population consisted of patients with CFS (n = 9), patients with QFS (n = 10), and healthy subjects (HSs) (n = 9). All subjects were women, matched for age (±5 years) and neighborhood, aged between 18 and 59 years, who did not use any medication other than paracetamol or oral contraceptives, and were not vaccinated in the last 6 months. None of the subjects reported substance abuse in the past 3 months or reported signs of underlying psychiatric disease on the Mini-International Neuropsychiatric Interview. All subjects underwent a [
RESULTS
No statistically significant differences in BP
DISCUSSION
In contrast to what was previously reported for CFS, we found no significant difference in BP
TRIAL REGISTRATION INFORMATION
EudraCT number 2014-004448-37.
Identifiants
pubmed: 34815320
pii: 9/1/e1113
doi: 10.1212/NXI.0000000000001113
pmc: PMC8611501
pii:
doi:
Substances chimiques
(R)-(11C)1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide
0
Amides
0
Isoquinolines
0
Receptors, GABA
0
TSPO protein, human
0
Banques de données
EudraCT
['2014-004448-37']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
J Psychosom Res. 2015 Oct;79(4):295-302
pubmed: 26272528
Popul Health Metr. 2005 Jul 22;3:8
pubmed: 16042777
Front Neurol. 2019 Jan 10;9:1033
pubmed: 30687207
Int J Clin Exp Med. 2012;5(3):208-20
pubmed: 22837795
J Nucl Med. 2009 Nov;50(11):1801-7
pubmed: 19837763
J Nucl Med. 2014 Jun;55(6):945-50
pubmed: 24665088
J Infect Dis. 2011 Nov 15;204(10):1632-40
pubmed: 21964398
Brain Behav Immun. 2019 Jan;75:72-83
pubmed: 30223011
Brain Behav Immun. 2020 Jul;87:498-507
pubmed: 32027960
Lancet. 2006 Jan 28;367(9507):346-55
pubmed: 16443043
PLoS One. 2017 Oct 24;12(10):e0186802
pubmed: 29065167
J Transl Med. 2017 Dec 29;15(1):267
pubmed: 29284500
Nat Rev Neurosci. 2014 May;15(5):300-12
pubmed: 24713688
J Infect. 2019 May;78(5):349-357
pubmed: 30684502
NMR Biomed. 2012 Sep;25(9):1073-87
pubmed: 22281935
Fatigue. 2017;5(1):15-20
pubmed: 29308330
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Horm Behav. 2018 Jul;103:1-6
pubmed: 29807037
PLoS One. 2016 May 25;11(5):e0155884
pubmed: 27223465
Hum Brain Mapp. 2003 Aug;19(4):224-47
pubmed: 12874777
Neuroimage. 2012 Apr 2;60(2):902-10
pubmed: 22251896
Med Care. 1981 Aug;19(8):787-805
pubmed: 7278416
Front Psychiatry. 2020 May 01;11:362
pubmed: 32425835
J Psychosom Res. 2017 Jun;97:45-51
pubmed: 28606498
Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5472-80
pubmed: 27573827
Glia. 2017 Sep;65(9):1423-1438
pubmed: 28608978
Clin Diagn Lab Immunol. 2005 Jan;12(1):52-5
pubmed: 15642984
Brain Behav Immun. 2015 Nov;50:186-195
pubmed: 26148446
Brain Imaging Behav. 2020 Apr;14(2):562-572
pubmed: 30617782
J Transl Med. 2019 May 14;17(1):157
pubmed: 31088495
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
BMC Health Serv Res. 2003 Dec 31;3(1):25
pubmed: 14702202
Sci Adv. 2015 Feb;1(1):
pubmed: 26079000
Cell. 2016 Nov 3;167(4):1111-1124.e13
pubmed: 27814508
J Psychosom Res. 1994 Jul;38(5):383-92
pubmed: 7965927
Clin Infect Dis. 2010 Jan 15;50(2):278-9
pubmed: 20034348
Transl Psychiatry. 2017 Apr 4;7(4):e1080
pubmed: 28375204
Lancet Psychiatry. 2020 Dec;7(12):1064-1074
pubmed: 33098761
Neuroscience. 2019 May 1;405:47-54
pubmed: 29292078